Physician profile
Abdul Malik
NPI 1255363339
$1,511.93
in general payments reported to CMS, 2019-2025
25 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $136 · 2023: $33.18 · 2024: $254 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $254.46 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $210.28 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $123.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $119.72 | 2019 | |
| Sunovion Pharmaceuticals INC. | $118.36 | 2019-2020 | |
| Bausch Health US, LLC | $85.55 | 2019-2024 | Wellbutrin |
| Avanir Pharmaceuticals, INC. | $66.96 | 2019 | |
| Jazz Pharmaceuticals INC. | $57.17 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.45 | 2019 | |
| Shire North American Group INC | $44.40 | 2019 | |
| Neos Therapeutics, Lp | $37.35 | 2019-2020 | |
| Allergan, INC. | $35.92 | 2019 | |
| Idorsia Pharmaceuticals US INC | $34.88 | 2023-2024 | Quviviq |
| Abiomed | $33.44 | 2025 | |
| Neurocrine Biosciences, INC. | $29.47 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $29.43 | 2024 | Loreev Xr |
| Alkermes, INC. | $24.71 | 2024 | Aristada, Lybalvi |
| Neuronetics, INC. | $24.69 | 2019 | |
| Owp Pharmaceuticals, INC. | $22.52 | 2019 | |
| Acadia Pharmaceuticals INC | $20.38 | 2019 | |
| Vertical Pharmaceuticals, LLC | $20.22 | 2019 | |
| Vanda Pharmaceuticals INC. | $20.04 | 2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $18.81 | 2023 | Dyanavel Xr |
| Lundbeck LLC | $18.13 | 2019 | |
| Corium, LLC | $15.90 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.